ANZAC: A Randomised Neoadjuvant Biomarker Study Investigating the Anti-Tumour Activity of the Addition of Zoledronic Acid to Chemotherapy in Breast Cancer

被引：1
|
作者：
Winter, M. C.
Syddall, S. P.
Cross, S. S.
Evans, A.
Ingram, C. E.
Jolley, I. J.
Hatton, M. Q.
Mori, S.
Holen, I.
Coleman, R. E.
机构：
[1] Univ Sheffield, Sheffield S10 2TN, S Yorkshire, England
[2] Sheffield Teaching Hosp NHS Fdn Trust, Sheffield, S Yorkshire, England
来源：
CANCER RESEARCH | 2010年 / 70卷
关键词：
D O I：
10.1158/0008-5472.SABCS10-P1-11-01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-11-01
引用
收藏
页数：1
相关论文
共 50 条
  • [1] ANZAC: A NEOADJUVANT BIOMARKER STUDY EXPLORING THE ANTI-TUMOUR ACTIVITY OF THE ADDITION OF ZOLEDRONIC ACID TO CHEMOTHERAPY IN BREAST CANCER
    Winter, M. C.
    Cross, S. S.
    Ingram, C. E.
    Jolley, I. J.
    Holen, I.
    Hatton, M. Q.
    Horsman, J. M.
    Coleman, R.
    [J]. ANNALS OF ONCOLOGY, 2009, 20 : 55 - 55
  • [2] The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer
    Coleman, R. E.
    Winter, M. C.
    Cameron, D.
    Bell, R.
    Dodwell, D.
    Keane, M. M.
    Gil, M.
    Ritchie, D.
    Passos-Coelho, J. L.
    Wheatley, D.
    Burkinshaw, R.
    Marshall, S. J.
    Thorpe, H.
    [J]. BRITISH JOURNAL OF CANCER, 2010, 102 (07) : 1099 - 1105
  • [3] The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer
    R E Coleman
    M C Winter
    D Cameron
    R Bell
    D Dodwell
    M M Keane
    M Gil
    D Ritchie
    J L Passos-Coelho
    D Wheatley
    R Burkinshaw
    S J Marshall
    H Thorpe
    [J]. British Journal of Cancer, 2010, 102 : 1099 - 1105
  • [4] Anti-tumour activity of zoledronic acid
    Clézardin, P
    [J]. CANCER TREATMENT REVIEWS, 2005, 31 : S1 - S8
  • [5] Neoadjuvant Chemotherapy with or without Zoledronic Acid in Early Breast Cancer-A Randomized Biomarker Pilot Study
    Winter, Matthew C.
    Wilson, Caroline
    Syddall, Stuart P.
    Cross, Simon S.
    Evans, Alyson
    Ingram, Christine E.
    Jolley, Ingrid J.
    Hatton, Matthew Q.
    Freeman, Jennifer V.
    Mori, Stefano
    Holen, Ingunn
    Coleman, Robert E.
    [J]. CLINICAL CANCER RESEARCH, 2013, 19 (10) : 2755 - 2765
  • [6] Molecular and preclinical models enhancing anti-tumour activity of zoledronic acid
    Marra, M.
    Santini, D.
    Tonini, G.
    Meo, G.
    Zappavigna, S.
    Facchini, G.
    Morabito, A.
    Abbruzzese, A.
    Carteni, G.
    Budillon, A.
    Caraglia, M.
    [J]. EJC SUPPLEMENTS, 2008, 6 (14): : 79 - 85
  • [7] Potential influence of zoledronic acid on primary tumour response during neoadjuvant chemotherapy for breast cancer
    Winter, Matthew
    Thorpe, Helen
    Burkinshaw, Roger
    Beevers, Samantha
    Coleman, Robert
    [J]. CANCER TREATMENT REVIEWS, 2008, 34 : S55 - S56
  • [8] The in vitro anti-tumour activity of zoledronic acid and docetaxel at clinically achievable concentrations in prostate cancer
    Morgan, Claire
    Lewis, Paul D.
    Jones, Rachel M.
    Bertelli, Gianfilippo
    Thomas, Gerry A.
    Leonard, Robert C. F.
    [J]. ACTA ONCOLOGICA, 2007, 46 (05) : 669 - 677
  • [9] Zoledronic Acid Reduces Breast Tumour Growth When Combined with Chemotherapy - Emerging Evidence of Anti-Tumour Effects Outside Bone
    Holen, I.
    Ottewell, P. D.
    Coleman, R. E.
    [J]. CANCER RESEARCH, 2010, 70
  • [10] The differential anti-tumour effects of zoledronic acid in breast cancer - evidence for a role of the activin signaling pathway
    Wilson, Caroline
    Ottewell, Penelope
    Coleman, Robert E.
    Holen, Ingunn
    [J]. BMC CANCER, 2015, 15
12345